Evidence at a glance
Status and evidence table
| Peptide | Canada status | Human evidence |
|---|---|---|
| PT-141 (Bremelanotide) | Not authorized in Canada (approved elsewhere) | Moderate: some randomized human trials, specific uses (small effects) |
| Melanotan I and II | Not authorized in Canada | Melanotan II: case reports of harm only; afamelanotide: RCTs in a rare disease |
| Kisspeptin | Not authorized in Canada | Limited: small or low-quality human studies (fertility research) |
| Oxytocin | Authorized in Canada (prescription) | Established for obstetric use; inconclusive for intranasal social/mood uses |
Status reflects Health Canada's peptide pages, its April 2026 advisory and the Drug Product Database as checked on November 10, 2026. Authorized products carry an 8-digit DIN (drugs) or NPN (natural health products).
